Patients with high-risk myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML) continue to exhibit poor outcomes, especially in the presence of high-risk features such as TP53 mutations or deletions (1–3) Thus, the development of effective therapies is urgently needed for these individuals. Here, TP53 is linked to acute myeloid leukemia.